Helmerich & Payne headed into its fiscal Q2 print on May 6 riding a 19% one-month rally and sitting at a 52-week high. What followed was a miss on both lines: adjusted EPS came in at -$0.38, against a consensus of -$0.02, and revenue of $932M fell short of the ~$950M estimate. The central tension for the week is therefore a stock that has run hard into a disappointing number — and what the lending market and analyst community make of that gap.
The short positioning gives the week some added texture. Short interest has been drifting lower — down around 3% on the week and nearly 10% from the late-April peak above 8.4 million shares — to roughly 7.9% of the free float. That is still a meaningful short position by any standard, but the direction of travel is cover, not accumulation. Borrow conditions remain very loose. Availability is ample and the cost to borrow has barely moved, hovering near 0.49% annually — a level that puts essentially no squeeze pressure on any remaining shorts. The ORTEX short score of 49.4, right in the middle of the 0-100 scale and easing from the mid-50s of a fortnight ago, confirms that short positioning has been unwinding as the stock has rallied.
Options traders were not braced for a big move going in. The put/call ratio of 0.50 is actually slightly below its 20-day average of 0.52, running about 1.3 standard deviations to the bullish side of recent norms. The ratio is also close to its 52-week low of 0.49, meaning options buyers have rarely been more tilted toward calls in the past year. That is a notable setup: into a print that missed on both top and bottom lines, options positioning was skewed toward upside. The earnings call on May 7 will be the next place to watch for management's framing of the shortfall.
The Street remains divided, and has been for months. Morgan Stanley maintained its Underweight rating as recently as April 15, lifting the target to $35 — still well below where the stock traded into the print at $41.53. Piper Sandler and Susquehanna are on the other side, both Overweight/Positive and raising targets into the $41-42 range through April. The consensus mean target of $38.40 now sits below the recent close, a configuration that typically tells you the bulls are already priced in and the bears are catching up on valuation. The EV/EBITDA at 6.97x and price-to-book at 1.53x have both expanded over 30 days — a reflection of the stock's strong run rather than fundamental re-rating.
The underlying fundamentals add another layer of complexity. The most recent quarterly figures show revenue of $932M but a reported net loss of nearly $97M. Normalised earnings tell a better story at around $10M, and EBITDA margins of 22% are respectable for the sector. Operating cash flow of $182M is solid. But the headline EPS miss — and the gap between reported and normalised — gives bears fresh ammunition, particularly with EPS surprise ranking in just the 3rd percentile of all stocks and the 90-day EPS momentum score a weak 23. The 30-day EPS momentum at the 91st percentile is the one bright spot, suggesting estimate revisions have been moving up sharply in the near term even if longer-run momentum is fading.
Peer performance this week has been mixed. Closest-correlated PTEN gained just under 5% on the week, broadly in line with H&P's 5.7% move. NBR was the clear outperformer, up 12.5%, while HAL and BKR lagged in the low single digits. The sector-wide lift appears oil-macro driven rather than stock-specific — making the earnings miss potentially more significant for H&P in isolation.
The next session after the May 7 earnings call will show how much the stock's one-year high was built on earnings expectations versus sentiment. With shorts covering, options skewed bullish into the print, and the actual results below consensus, the setup entering the call is one where the price of forgiveness may already be embedded in the tape.
See the live data behind this article on ORTEX.
Open HP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
